Products2018-12-27T16:21:09+00:00

Four Product Development Candidates

Product Indications
TCEL-100 Solid tumors
TCEL-200 Solid tumors
TT-300 Pancreatic, Colorectal, Lung
TT-400 Solid tumors

Preclinical Phase I Phase II
TCEL-100
TCEL-200
TT-300
TT-400

Product Development Candidates

TCEL-100

TCEL-100 is a preclinical candidate.  T-CEL-100 is an adoptive cell therapy product consisting of T-cells expanded from tumor infiltrating lymphocytes.  The T-cells were selected based on the profile of selection markers indicative of potential for tumor reactivity.  T-CEL-100 is polyclonal, meaning it targets multiple neoantigens expressed by the tumors.

TCEL-200

TCEL-200 is a preclinical candidate.  TCEL-200 is an adoptive cell therapy product consisting of T-cells expanded from tumor infiltrating lymphocytes.  The T-cells were selected based on the profile of selection markers indicative of potential for tumor reactivity.  Further, the T-cells selected for expansion were assessed for their ability to recognize and bind to peptides expressed by the patient’s immune system cells, ex-vivo.  TCEL-200 is polyclonal, meaning it potentially targets multiple neoantigens expressed by the tumors.

TT-300

TT-300 is a preclinical candidate.  TT-300 is an adoptive cell therapy product consisting of T-cells engineered to express the receptor to a neoantigen, in this case a common driver mutation.  TT-300 will be evaluated in patients harboring the target mutation.  

TT-400

TT-400 is a preclinical candidate.  TT-400 is an adoptive cell therapy product consisting of T-cells engineered to express the receptor to a neoantigen, in this case a common driver mutation.   TT-400 will be evaluated in patients harboring the targeted mutations.